At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 99 enrolled
Drug / intervention
LY2969822 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY2969822 and Placebo for Healthy Volunteers. Completed, enrolled 99 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate how safe LY2969822 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. This is the first time that this study drug is being given to participants. This study is for research purposes only and is not intended to treat any medical condition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionFeb 2015
TodayJul 2026
First PostedDec 23, 2013
Enrollment StartDec 1, 2013
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.5 years ago
Interventions
LY2969822drug
Capsules administered orally
Placebodrug
Capsules administered orally